velcade
- Product Details
- Company Profile
Bortezomib, marketed as Velcade by Millennium Pharmaceuticals, is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.
1. The basic information of Bortezomib (velcade)
CAS NO : 179324-69-7
Bortezomib Molecular Weight: 384.24
Molecular Formula: C19H25BN4O4
Boiling Point: 130.5°C (266.9°F)
Melting Point: -23°C (-9.4°F)
Bortezomib structure:
2. The process of Bortezomib synthesis
Hangzhou Holypharm biotech Co.,Ltd is a professional supplier of active pharmaceutical ingredients and intermediates, agrochemicals and Veterinary products at present. The following is the process of Bortezomib synthesis given by them.
3. How velcade (bortezomib) Works
Velcade is an important option for treating patients with multiple myeloma and patients with relapsed mantle cell lymphoma (MCL) because it gives you another way to fight your disease. Velcade is a type of medicine called a proteasome (pro-tee-uh-zohm) inhibitor. It is the only proteasome inhibitor the FDA has approved.
Velcade is a proteasome inhibitor that temporarily blocks, or inhibits, proteasomes from breaking down proteins. This causes a buildup of proteins in the cell. When there are too many proteins in the cells, the cells stop growing and die.
Verified Supplier
HANGZHOU HOLYPHARM BIOTECH CO.,LTD
- Country: China (Mainland)
- Year Established: 2009
- Business License:
- Business type: Other
- Integral:
Contact Details|Similar Products
Escrow ServiceMore
Secure Your Orders With escrow More Transparency,Less Uncertainty